A new drug developed by Taipei-based Foresee Pharmaceuticals Co. to treat acute respiratory distress syndrome (ARDS) in COVID-19 patients has received the approval of an independent data monitoring committee (IDMC) in the United States.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
- Politics
Taiwan's deputy representative to India dies during event
12/12/2025 09:37 PM - Politics
KMT passes legislation reversing DPP's 2018 pension reform
12/12/2025 09:32 PM - Politics
Motions seeking Lai defense briefing sent to 2nd reading, negotiations
12/12/2025 09:01 PM - Society
5 detained on suspicion of dumping marine fuel waste in Keelung River
12/12/2025 08:59 PM